Genomic Alterations in Leukemia (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 64
Special Issue Editor
Interests: acute myeloid leukemia; acute lymphoblastic leukemia; genomics; functional modeling; targeted therapy; genome editing; single-cell sequencing
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Acute leukemias, including both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), are driven by constellations of genetic alterations with clinical, prognostic and therapeutic implications. The detection of these alterations and their associated transcriptional signatures is crucial for diagnosis, risk assessment and treatment. The dynamic and intricated heterogeneity of leukemic cells with the expansion of resistant clones may promote disease persistence or recurrence. Recently, the use of single-cell technologies has enabled us to dissect clonal heterogeneity, refine cell developmental state composition and explore interactions with the microenvironment, enhancing our understanding of acute leukemia pathogenesis and therapeutic responsiveness.
Rapid progress in genetic discovery has been accompanied by the growing development of faithful cellular and in vivo models, such as genetically engineered mice and xenografts of patient-derived cells in immune-deficient mice, which have elucidated the role of leukemia drivers and highlighted the importance of cellular origin.
Moreover, recent advances in computational analysis methods and machine learning models offer opportunities to advance diagnosis, predict prognosis, and guide therapy.
This Special Issue will highlight the current state of the art in both ALL and AML and discuss future perspectives to improve the analysis of acute leukemia at both bulk and single-cell resolution and advance clinical management and therapeutic approaches.
Dr. Ilaria Iacobucci
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute leukemia
- functional genomics
- classification
- single cells
- germline predisposition
- mouse models
- genome editing
- machine learning
- therapeutic targeting
